Q1 EPS Forecast for Dianthus Therapeutics Lifted by Analyst

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Dianthus Therapeutics in a research report issued on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.03) per share for the quarter, up from their prior estimate of ($1.21). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.

A number of other research firms have also recently commented on DNTH. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, Guggenheim reissued a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Trading Up 3.0 %

Dianthus Therapeutics stock opened at $21.97 on Monday. Dianthus Therapeutics has a 1-year low of $18.13 and a 1-year high of $33.77. The firm has a market capitalization of $650.25 million, a PE ratio of -8.79 and a beta of 1.82. The firm’s 50 day simple moving average is $22.44 and its 200 day simple moving average is $24.76.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently made changes to their positions in the business. TCG Crossover Management LLC bought a new stake in Dianthus Therapeutics in the 4th quarter worth $32,735,000. Braidwell LP grew its holdings in Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after acquiring an additional 712,902 shares during the last quarter. Vestal Point Capital LP grew its holdings in Dianthus Therapeutics by 172.2% in the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after acquiring an additional 680,000 shares during the last quarter. State Street Corp grew its holdings in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Finally, Octagon Capital Advisors LP grew its holdings in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after acquiring an additional 363,500 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.